A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Johnson & Johnson Enterprise Innovation Inc. to Johnson & Johnson Enterprise Innovation Inc.
    • Study completion moved earlier from Jun 7, 2029 to Nov 30, 2027
    • Eligibility criteria expanded, about 11 words
  2. Enrollment closed, study ongoing
    • Final enrollment: 67 participants (planned 126)
    • Site details revised at 15 of 15 sites
    v39
  3. Re-verified, no change to tracked fieldsv38
  4. Study description expanded, about 24 wordsv37
  5. Re-verified, no change to tracked fieldsv36
Show 34 earlier versionsHide 34 earlier versions
  1. Study sites revised (15)v35
  2. 3 versions Re-verified since Jan 15, 2026, no change to tracked fieldsv32-v34
  3. Study sites: 14 to 15v31
  4. Study sites: 13 to 14v30
  5. 2 versions Re-verified since Sep 11, 2025, no change to tracked fieldsv28-v29
  6. Study sites: 12 to 13v27
  7. Re-verified, no change to tracked fieldsv26
  8. Study sites: 10 to 12v25
  9. 4 versions Re-verified since Mar 27, 2025, no change to tracked fieldsv21-v24
  10. Eligibility criteria shortened, about 277 words
    • Secondary endpoints: 12 to 6
    v20
  11. Enrollment target: 76 to 126
    • Study completion date: Aug 3, 2028 to Jun 7, 2029
    v19
  12. 5 versions Re-verified since Sep 10, 2024, no change to tracked fieldsv14-v18
  13. Study completion date: Jul 27, 2028 to Aug 3, 2028v13
  14. Study sites revised (10)v12
  15. Study sites revised (10)v11
  16. Study sites: 9 to 10v10
  17. Study sites: 7 to 9v9
  18. Study sites: 4 to 7v8
  19. Re-verified, no change to tracked fieldsv7
  20. Study sites: 3 to 4v6
  21. Re-verified, no change to tracked fieldsv5
  22. Start date changed from estimate of Nov 20, 2023 to Nov 27, 2023v4
  23. Study sites: 2 to 3v3
  24. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date: Nov 29, 2023 to Nov 20, 2023
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
Trial Details
NCT Number NCT06116786
Lead Sponsor Johnson & Johnson Enterprise Innovation Inc.
Conditions
(from sponsor)		 Carcinoma, Non-small-Cell Lung
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 67 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov